Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led by investigators at the Abramson Family Cancer Center at the University of Pennsylvania Perelman School of Medicine.
Opinion | ‘More and More Patients in Less and Less Time’: What We Heard This Week
“It feels like we’re being asked to see more and more patients in less and less time.” — Meghan Lelonek, MD, a hospitalist with Sound
June 3, 2024